keyword
MENU ▼
Read by QxMD icon Read
search

Second line treatment

keyword
https://www.readbyqxmd.com/read/29166136/the-gamma-aminobutyric-acid-b-receptor-gabab-encephalitis-clinical-manifestations-and-response-to-immunotherapy
#1
Junzhao Cui, Hui Bu, Junying He, Zeyan Zhao, Weixin Han, Ruiping Gao, Xiaoqing Li, Qing Li, Xiaosu Guo, Yueli Zou
PURPOSE: We report 11 patients diagnosed with GABAB receptor (GABABR) antibodies encephalitis in China and aim to analyse the clinical characteristics, laboratory and imaging findings, therapeutic modalities and outcomes. METHODS: Clinical data from patients diagnosed with anti-GABAB receptor encephalitis in the Second Affiliated Hospital of Hebei Medical University from February 2016 to October 2016 January were retrospectively collected and evaluated. RESULTS: Seven of the eleven patients were males, and a mean age at presentation of 63 years (range: 47-79 years)...
November 22, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/29166129/initial-observations-of-intra-and-inter-fractional-motion-variation-in-mr-guided-lung-sbrt
#2
David H Thomas, Anand Santhanam, Amar U Kishan, Minsong Cao, James Lamb, Yugang Min, Dylan O'Connell, Yingli Yang, Nzhde Agazaryan, Percy Lee, Daniel Low
OBJECTIVE: To evaluate variations in intra- and inter-fractional tumor motion, and the effect on ITV contour accuracy, using deformable image registration of real-time 2D-sagital cine-mode MRI acquired during lung SBRT treatments. METHODS: Five lung tumor patients underwent free breathing SBRT treatments on the ViewRay system, with dose prescribed to a planning target volume (PTV; defined as a 3-6 mm expansion of the 4DCT-ITV). Sagittal slice cine-MR images (3.5x3...
November 22, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/29165716/targeting-bcr-abl-independent-tki-resistance-in-chronic-myeloid-leukemia-by-mtor-and-autophagy-inhibition
#3
Rebecca Mitchell, Lisa E M Hopcroft, Pablo Baquero, Elaine K Allan, Kay Hewit, Daniel James, Graham Hamilton, Arunima Mukhopadhyay, Jim O'Prey, Alan Hair, Junia V Melo, Edmond Chan, Kevin M Ryan, Véronique Maguer-Satta, Brian J Druker, Richard E Clark, Subir Mitra, Pawel Herzyk, Franck E Nicolini, Paolo Salomoni, G Vignir Helgason
Background: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a major clinical challenge. Although ponatinib, a third-generation TKI, improves outcomes for patients with BCR-ABL-dependent mechanisms of resistance, including the T315I mutation, a proportion of patients may have or develop BCR-ABL-independent resistance and fail ponatinib treatment...
November 20, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29164917/efficacy-and-safety-of-palbociclib-in-heavily-pretreated-patients-with-hr-her2-%C3%A2-metastatic-breast-cancer
#4
Marija Ban, Branka Petrić Miše, Ana Majić, Ivanka Dražić, Eduard Vrdoljak
AIM: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. METHODS: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. RESULTS: A total of 58.3% patients achieved stable disease. No objective response was observed...
November 22, 2017: Future Oncology
https://www.readbyqxmd.com/read/29164403/a-novel-photodynamic-therapy-based-drug-delivery-system-layered-on-a-stent-for-treating-cholangiocarcinoma
#5
Po-Chin Liang, Kai-Wen Huang, Chien-Chih Tung, Ming-Chu Chang, Fuh-Yu Chang, Jau-Min Wong, Yu-Ting Chang
This study aimed to investigate the drug delivery efficacy and bio-effectiveness of a novel photodynamic therapy (PDT)-matrix drug delivery system for cholangiocarcinoma (CCA). Metallic stents were coated with polyurethane (PU) as the first layer. A 2-hydroxyethyl methacrylate (2-HEMA)/ethylene glycol dimethacrylate (EGDMA)/benzoyl peroxide (BPO) layer and a poly(ethylene-co-vinyl acetate) (PEVA)/poly(n-butyl methacrylate) (PBMA)/polyvinylpyrrolidone K30 (K30) layer containing various concentrations of Photofrin were then incorporated onto the stent as the second and third layers...
November 22, 2017: Biomedical Microdevices
https://www.readbyqxmd.com/read/29163934/determinants-of-integrated-management-of-childhood-illness-imci-non-severe-pneumonia-classification-and-care-in-malawi-health-facilities-analysis-of-a-national-facility-census
#6
Emily White Johansson, Humphreys Nsona, Liliana Carvajal-Aguirre, Agbessi Amouzou, Helena Hildenwall
Background: Research shows inadequate Integrated Management of Childhood Illness (IMCI)-pneumonia care in various low-income settings but evidence is largely from small-scale studies with limited evidence of patient-, provider- and facility-levels determinants of IMCI non-severe pneumonia classification and its management. Methods: The Malawi Service Provision Assessment 2013-2014 included 3149 outpatients aged 2-59 months with completed observations, interviews and re-examinations...
December 2017: Journal of Global Health
https://www.readbyqxmd.com/read/29163815/pd-l1-expression-heterogeneity-in-non-small-cell-lung-cancer-evaluation-of-small-biopsies-reliability
#7
Enrico Munari, Giuseppe Zamboni, Marcella Marconi, Marco Sommaggio, Matteo Brunelli, Guido Martignoni, George J Netto, Francesca Moretta, Maria Cristina Mingari, Matteo Salgarello, Alberto Terzi, Vincenzo Picece, Carlo Pomari, Gianluigi Lunardi, Alberto Cavazza, Giulio Rossi, Lorenzo Moretta, Giuseppe Bogina
Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50% of neoplastic cells and as a second line treatment for patients with NSCLC expressing PD-L1 in ≥1% of neoplastic cells, evaluated with a validated assay...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29162397/biosimilar-filgrastim-leucostim%C3%A2-have-similar-efficacy-in-steady-state-hematopoietic-progenitor-cell-mobilization-compared-to-original-filgrastim-neupogen%C3%A2-and-lenograstim-granocyte%C3%A2-a-retrospective-multicenter-study
#8
Ömür Kayıkçı, Emre Tekgündüz, Ali Hakan Kaya, Hakan Göker, Alma Aslan, Dicle İskender, Sinem Namdaroglu, Aysegul Tetik, Şerife Koçubaba, Fevzi Altuntaş
Biosimilar filgrastim (Leucostim(®)) was shown to be similar in terms of efficacy and safety in hematopoietic progenitor cell mobilization (HPCM) compared to originator filgrastim (Neupogen(®)) and lenograstim (Granocyte(®)) in healthy donors and chemomobilization settings. Here we report our retrospective experience with Leucostim(®) (n: 43) compared to Neupogen(®) (n: 71) and Granocyte(®) (n: 32) in steady-state mobilization of patients presenting with Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma...
November 10, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29162045/serial-pseudoprogression-of-metastatic-malignant-melanoma-in-a-patient-treated-with-nivolumab-a-case-report
#9
Yukinori Ozaki, Junichi Shindoh, Yuji Miura, Hiromichi Nakajima, Ryosuke Oki, Miyuki Uchiyama, Jun Masuda, Keiichi Kinowaki, Chihiro Kondoh, Yuko Tanabe, Tsuyoshi Tanaka, Shusuke Haruta, Masaki Ueno, Shigehisa Kitano, Takeshi Fujii, Harushi Udagawa, Toshimi Takano
BACKGROUND: Pseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been reported previously, there have been no case reports yet of pseudoprogression events documented twice during treatment. CASE PRESENTATION: A 55-year-old man underwent surgery for locally advanced esophageal malignant melanoma and received postoperative adjuvant interferon therapy...
November 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29161753/improving-the-efficacy-of-proteasome-inhibitors-in-the-treatment-of-renal-cell-carcinoma-by-combination-with-the-hiv-protease-inhibitors-lopinavir-or-nelfinavir
#10
Dominik Abt, Andrej Besse, Lenka Sedlarikova, Marianne Kraus, Juergen Bader, Tobias Silzle, Martina Vodinska, Ondrej Slaby, Hans-Peter Schmid, Daniel Stephan Engeler, Christoph Driessen, Lenka Besse
OBJECTIVES: To assess the potential of second-generation proteasome inhibition by carfilzomib and its combination with the HIV-protease inhibitors (HIV-PIs) lopinavir and nelfinavir in vitro for improved treatment of clear cell renal cell cancer (ccRCC). MATERIALS AND METHODS: Cytotoxicity, reactive oxygen species (ROS) production and unfolded protein response (UPR) activation of proteasome inhibitors, HIV-PIs and their combination was assessed in 3 cell lines and primary cells derived from 3 ccRCC tumors by MTS assay, flow cytometry, quantitative PCR and western blot, respectively...
November 21, 2017: BJU International
https://www.readbyqxmd.com/read/29161084/mitochondrial-dysfunction-linking-obesity-and-asthma
#11
Naveen K Bhatraju, Anurag Agrawal
The bidirectional epidemiological association between asthma and obesity is well known. Recent evidence suggests that there is an intersection of the pathophysiological molecular pathways leading to either obesity or asthma, at the level of mitochondria. This is not surprising, because mitochondria, beyond their roles as the metabolic powerhouses of the cell, serve as sensors of threats, regulators of stress signaling, and effectors of cytotoxicity. Reduced mitochondrial function and low metabolic activity are well-recognized features of obesity...
November 2017: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/29159580/low-left-amygdala-volume-is-associated-with-a-longer-duration-of-unipolar-depression
#12
Maxim Zavorotnyy, Rebecca Zöllner, L R Schulte-Güstenberg, L Wulff, S Schöning, U Dannlowski, H Kugel, V Arolt, C Konrad
The amygdala plays a crucial role in the pathogenesis of major depressive disorder (MDD). While robust findings support a negative impact of illness duration on hippocampal volume in MDD, morphometric studies of the amygdala have yielded inhomogeneous results. Considering the methodical problems of automatic segmentation methods, a standardized segmentation protocol with proven inter- and intra-rater reliability was employed using high-resolution magnetic resonance imaging. To identify the effect of MDD on amygdala morphometry, 23 unipolar depressed patients who responded to antidepressant medication and 30 age-matched healthy controls (HC) were enrolled...
November 20, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29158981/fitness-implications-of-sex-specific-catch-up-growth-in-nephila-senegalensis-a-spider-with-extreme-reversed-ssd
#13
Rainer Neumann, Nicole Ruppel, Jutta M Schneider
Background: Animal growth is often constrained by unfavourable conditions and divergences from optimal body size can be detrimental to an individual's fitness, particularly in species with determinate growth and a narrow time-frame for life-time reproduction. Growth restriction in early juvenile stages can later be compensated by means of plastic developmental responses, such as adaptive catch-up growth (the compensation of growth deficits through delayed development). Although sex differences regarding the mode and degree of growth compensation have been coherently predicted from sex-specific fitness payoffs, inconsistent results imply a need for further research...
2017: PeerJ
https://www.readbyqxmd.com/read/29158727/near-complete-response-in-a-patient-with-classical-hodgkin-lymphoma-treated-with-brentuximab-vedotin-concurrent-with-radiation-therapy
#14
Wilbur Montana, Dennis Andrew Buck, Tristan Smith
Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior multi-agent chemotherapy regiments. This approval was based on a study that showed an overall response rate of 75% and complete remission in 34%. We present a case of a 24-year-old male with classical nodular sclerosing Hodgkin lymphoma who achieved near complete remission following 5 cycles of brentuximab concurrent with ISRT (involved site radiation therapy) following progression of first-line ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) and subsequent second-line ICE (ifosfamide, carboplatin, etoposide) chemotherapy...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29158101/effect-of-hiv-1-low-level-viraemia-during-antiretroviral-therapy-on-treatment-outcomes-in-who-guided-south-african-treatment-programmes-a-multicentre-cohort-study
#15
Lucas E Hermans, Michelle Moorhouse, Sergio Carmona, Diederick E Grobbee, L Marije Hofstra, Douglas D Richman, Hugo A Tempelman, Willem D F Venter, Annemarie M J Wensing
BACKGROUND: Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries. WHO guidelines for these regions define failure of ART with a lenient threshold of viraemia (HIV RNA viral load ≥1000 copies per mL). We investigated the occurrence of detectable viraemia during ART below this threshold and its effect on treatment outcomes in a large South African cohort...
November 17, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29158079/bone-metastases-as-the-only-metastatic-site-in-patients-with-urothelial-carcinoma-focus-on-a-special-patient-population
#16
Andrea Necchi, Gregory R Pond, Sumanta K Pal, Neeraj Agarwal, Daniel W Bowles, Elizabeth R Plimack, Evan Y Yu, Sylvain Ladoire, Jack Baniel, Simon Crabb, Gunter Niegisch, Sandy Srinivas, Dominik R Berthold, Jonathan E Rosenberg, Thomas Powles, Aristotelis Bamias, Lauren C Harshman, Joaquim Bellmunt, Matthew D Galsky
BACKGROUND: Patients with exclusive bone metastatic spread from urothelial carcinoma (UC) throughout their disease course represent a rare subgroup with unique clinical features. These patients deserved special consideration in a retrospective multicenter study. PATIENTS AND METHODS: Analyses were made from a pool of 1911 patients with a diagnosis of metastatic UC, from 23 centers. Baseline characteristics, access to treatment, and outcomes were analyzed according to metastatic spread...
November 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29157477/spontaneous-dissection-of-superior-mesenteric-artery-long-term-outcome-of-stent-placement
#17
Junghoon Kim, Chang Jin Yoon, Nakjong Seong, Hyukjoon Lee, Young-Joo Kim
Stent placement was performed in 10 patients with symptomatic spontaneous dissection of the superior mesenteric artery (SMA). A stent was placed as first-line treatment in 7 patients and as second-line treatment in 3 patients in whom conservative treatment had failed. Abdominal pain completely resolved within 2 days after stent placement, and follow-up (median 53 months; range, 11-99 months) CT angiography revealed complete obliteration of the false lumen and good stent patency in 9 patients. One patient showed asymptomatic stent occlusion at 99-month follow-up...
December 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29157296/biomarkers-for-immunotherapy-in-bladder-cancer-a-moving-target
#18
REVIEW
David H Aggen, Charles G Drake
Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1 antibody pembrolizumab demonstrated improved OS relative to chemotherapy in a randomized phase III study for second line treatment of mUC; this level 1 evidence led to approval from the U...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29156852/risk-factors-for-recurrent-central-line-associated-bloodstream-infections-in-a-pediatric-intensive-care-unit
#19
Rana İşgüder, İlker Devrim, Gökhan Ceylan, Ahu Kara, Gamze Gülfidan, Hasan Ağın
Background/aim: It is recommended that a central venous catheter (CVC) be removed if central line-associated bloodstream infection (CLABSI) has been diagnosed. The objective of this retrospective study was to evaluate the risk factors for recurrent CLABSI in reinserted catheters in a pediatric intensive care unit. Materials and methods: Patients with recurrent and nonrecurrent CLABSI were compared in terms of the catheter exchange interval, the interval between negative blood culture and reinsertion of the CVC, and the pre-/reinsertion treatment duration...
August 23, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/29156777/patients-with-nsclc-may-display-a-low-ratio-of-p-t790m-vs-activating-egfr-mutations-in-plasma-at-disease-progression-implications-for-personalised-treatment
#20
Marzia Del Re, Paola Bordi, Iacopo Petrini, Eleonora Rofi, Francesca Mazzoni, Lorenzo Belluomini, Enrico Vasile, Giuliana Restante, Francesco Di Costanzo, Alfredo Falcone, Antonio Frassoldati, Ron H N van Schaik, Christi M J Steendam, Antonio Chella, Marcello Tiseo, Riccardo Morganti, Romano Danesi
Introduction: NSCLC harboring activating mutations of EGFR is highly sensitive to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed information on the amount of p.T790M plasmatic level associated with resistance to EGFR-TKIs and guidance to treatment with p.T790M-effective TKI depending on these levels, is lacking. Methods: This study enrolled p.T790M-positive patients (n=49) affected by EGFR-mutated NSCLC at progression to first-line EGFR-TKIs and, in selected cases (n=5), after second-line treatment with osimertinib...
October 17, 2017: Oncotarget
keyword
keyword
55342
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"